Phase I trial of SPX 106t, a fixed-dose combination of D-tagatose and SPX 106.
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2012
At a glance
- Drugs D-tagatose/SPX 106 (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia
- Focus Adverse reactions
- 13 Aug 2012 Planned initiation date changed from 1 Jun 2012 to 1 Dec 2012, as reported in a Spherix media release.
- 11 Jan 2012 Planned initiation date changed from 1 Mar 2012 to 1 Jun 2012, according to a Spherix Incorporated media release.
- 09 Jun 2011 New trial record